Pirtobrutinib User Reviews & Ratings
Brand names: Jaypirca
Pirtobrutinib has an average rating of 7.0 out of 10 from a total of 2 reviews on Drugs.com. 50% of reviewers reported a positive experience, while 0% reported a negative experience.
| Condition | Avg. Rating | Reviews | Compare |
|---|---|---|---|
| Mantle Cell Lymphoma | 2 reviews for Mantle Cell Lymphoma | 10 medications | |
| Add your review | |||
- Jack
- Taken for 1 to 6 months
- May 4, 2024
Jaypirca (pirtobrutinib) for Mantle Cell Lymphoma "Worked quickly to control MCL after Brukinsa stopped working. Also taking Rituximab. Some bruising. Have been taking for one month."
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about pirtobrutinib
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: BTK inhibitors
- Breastfeeding
- En español
For Mantle Cell Lymphoma "I have been on Pirtobrutinib for 10 weeks. I am experiencing lower leg swelling, shortness of breath doing any exertion, and fatigue. I conclude that the side effects are tolerable as long as the pill is working, and my oncologist is pleased with my progress."